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Upon ligand activation, the epidermal growth factor
receptor (EGFR) becomes tyrosine-phosphorylated,
thereby recruiting intracellular signaling proteins such
as Shc. EGFR binding of Shc proteins results in their
tyrosine phosphorylation and subsequent activation of
the Ras and Erk pathways. Shc interaction with acti-
vated receptor tyrosine kinases is mediated by two dis-
tinct phosphotyrosine interaction domains, an NH2-ter-
minal phosphotyrosine binding (PTB) domain and a
COOH-terminal Src homology 2 (SH2) domain. The rel-
ative importance of these two domains for EGFR bind-
ing was examined by determining if expression of the
isolated SH2 or PTB domain of ShcC would inhibit
EGFR signaling. The SH2 domain potently inhibited nu-
merous aspects of EGFR signaling including activation
of Erk2 and the Elk-1 transcription factor as well as
EGFR-dependent transformation. Furthermore, the SH2
domain inhibited focus formation by the Neu oncopro-
tein, another EGFR family member. Surprisingly, inhi-
bition of the EGFR by the SH2 domain did not involve
stable association with the receptor. In contrast, the
PTB domain associated quite well with the receptor yet
had little effect on EGFR signaling. Although the EGFR
cytoplasmic tail contains consensus binding sites for the
PTB and SH2 domains of ShcC, and both domains of
ShcC interact with the receptor in vitro, the SH2 domain
is more potent for inhibiting receptor function in vivo.
However, inhibition is not due to stable association with
the receptor, suggesting that the SH2 domain is binding
to a heretofore unknown protein(s) necessary for proper
EGFR function.
The regulation of intracellular signaling cascades through
the binding of peptide growth factors by membrane-bound
RTKs1 is important for regulation of cellular growth, differen-
tiation, apoptosis, and oncogenesis. RTKs regulate a multitude
of intracellular signaling pathways. One such pathway in-
volves the Shc adaptor proteins. Shc proteins are part of a
diverse family of proteins encoded by at least three separate
genes, shcA, shcB, and shcC (1–4). All Shc proteins share a
similar structural arrangement that includes an NH2-terminal
phosphotyrosine binding domain (PTB), a central Gly- and
Pro-rich region (CH1), and a COOH-terminal Src homology 2
domain (SH2). In addition, each gene encodes multiple splice
forms that may possess distinct activities (5, 6).
In particular, Shc proteins are thought to link RTKs with
regulation of the Ras pathway (7). Shc proteins bind the adap-
tor protein Grb2, which, like Shc proteins, also possesses an
SH2 domain in addition to two flanking SH3 domains. Grb2
physically associates with the Ras guanine nucleotide ex-
change factor, Sos, through its SH3 domains. Upon activation
of the EGFR, Shc binds the phosphorylated receptor and itself
becomes tyrosine-phosphorylated, leading to the recruitment of
the Grb2-Sos complex to the plasma membrane in close prox-
imity to Ras, thus leading to Ras activation.
Although the above model provides a molecular basis for our
understanding of how RTKs lead to Ras activation, a number of
important questions remain unanswered. First, the importance
of Shc in EGFR activation of Ras is not clear, since the EGFR
can bind Grb2 directly in lieu of a Shc intermediary. Second,
the presence of two distinct phosphotyrosine binding domains
in Shc (PTB versus SH2) suggests that Shc may link to ty-
rosine-phosphorylated proteins in different manners. Further-
more, the EGFR contains two binding sites for Shc, an SH2
binding site (Tyr1173) and a PTB binding site (Tyr1148), whereas
other receptors, such as the nerve growth factor receptor, con-
tain only a PTB binding site, suggesting that Shc proteins may
function differently with different RTKs. However, the impor-
tance of direct binding of Shc to the EGFR is unclear given that
mutant versions of the EGFR that lack the tyrosine autophos-
phorylation sites, and hence the Shc binding sites, are still
mitogenic and capable of activating Shc, suggesting that abro-
gation of Shc interaction with the EGFR may not affect Ras
activation by the receptor (8–10). Finally, recent data have
indicated that Shc may also function in Ras-independent path-
ways, suggesting that Shc may perform other functions besides
regulation of the Ras/Erk pathway (11–20).
To define the importance of Shc in EGFR function, we as-
sessed the ability of the isolated PTB and SH2 domains of ShcC
to act as dominant negative inhibitors of EGFR signaling and
transformation. We found that the SH2 domain inhibited
EGFR activation of Erk-2 and Elk-1 and the growth of EGFR-
transformed cells in soft agar in the absence of stable associa-
tion with the receptor. In contrast, we found that the PTB
domain formed a stable complex with the activated receptor yet
did not significantly inhibit the activation of Erk-2 or Elk-1 by
the receptor. These observations suggest that the ShcC SH2,
rather than the PTB, mediates EGFR activation of Erk/Elk-1
and growth transformation. Furthermore, we suggest that the
ShcC SH2 domain may promote this function via interaction
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with an as yet to be defined cellular component other than the
EGFR.
EXPERIMENTAL PROCEDURES
Cell Lines and Constructs—293-T cells, hereafter referred to as 293
cells (kindly provided by Dr. Brian Howell, Fred Hutchinson Cancer
Research Center), are a human embryonic kidney cell line expressing
simian virus 40 T antigen. 293 cells and NIH/3T3 cells (kindly provided
by Dr. Edison Liu, University of North Carolina) were maintained in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum,
penicillin, and streptomycin. The murine luekemia virus-EGFR expres-
sion construct encodes the wild type human EGFR and was kindly
provided by Dr. Alan Wells (University of Alabama at Birmingham).
The pSV2-NeuT plasmid encodes a point-mutated, activated Neu onco-
protein (21) and was kindly provided by Dr. Ming-Chi Huang (MD
Anderson Cancer Center, University of Texas).
The ShcC PTB and SH2 domains were subcloned into the pCGN-hyg
expression vector, which encodes a hemagglutinin (HA) epitope se-
quence at the 59-end of the subcloned cDNA fragments (22). Each
construct was made as follows. The PTB domain expressed in these
experiments extends from the second residue of ShcC (2). The cDNA
sequence encoding the ShcC PTB domain (amino acids 2–212) was
PCR-amplified to create a BamHI site in frame with codon 2. This
fragment was subcloned into the pCRII vector (Stratagene), sequenced
to check for mutations, and then subcloned into the BamHI site of
pCGN-hyg as a BamHI–BglII fragment. The cDNA sequence encoding
the SH2 domain of ShcC was PCR-amplified as described previously (2).
The resulting product was subcloned into the pCRII cloning vector and
sequenced to check for mutations. The 59-PCR oligonucleotide for the
SH2 domain contained a BamHI site, which, in conjuction with the
BamHI site in pCRII, was used to subclone the SH2 domain into the
BamHI site of pCGN-hyg.
The pCGN Grb2 SH2 (kindly provided by Dr. Lawrence Quilliam,
University of Indiana) encodes amino acids 56–155 of human Grb2, a
sequence that corresponds to the isolated SH2 domain. The pCGN
p120GAP SH2-SH3-SH2 construct (kindly provided by Dr. Geoff Clark,
University of North Carolina) encodes amino acids 181–443 of human
p120GAP. The construct contains a stop codon between the sequence
encoding the HA epitope tag and the initiating Met of the GAP se-
quence; therefore, the resulting protein product is not recognized by the
HA monoclonal antibody. The SrcY527F construct encodes a constitu-
tively activated avian Src mutated at amino acid 527 and was kindly
provided by Dr. Brian Howell. The NPM-ALK construct encodes the
NPM-ALK translocation (23) and was kindly provided by Dr. Steve
Morris (St. Jude Children’s Research Hospital).
Gal-Luciferase and MAPK Activation Assays—Elk-1 activation was
measured using a transient transcriptional activation assay essentially
as described previously (24). Briefly, 293 cells were transfected with
constructs encoding a Gal-Elk fusion protein along with a Gal-luciferase
reporter construct. In addition to these constructs, cells were cotrans-
fected with the various dominant negative constructs. 293 cells (1.25 3
105 per well) were plated in six-well tissue culture plates. On the
following day, a mixture of the following DNAs was transfected into
each well of a six-well tissue culture plate by the calcium phosphate
precipitation method: 2.5 mg of 53 Gal-luciferase, 0.5 mg of Gal-Elk, 1
mg of dominant negative and 1 mg of calf thymus DNA (Boehringer
Mannheim). DNAs were mixed in H20 (112.5 ml/well). To the mixture
was added dropwise with gentle mixing 12.5 ml of 2.5 M CaCl2. The
DNA/CaCl2 mixture was then added dropwise with gentle agitation to
an equal volume of 23 HEPES-buffered saline (280 mM NaCl, 50 mM
HEPES, 1.5 mM Na2HPO4z12H2O, pH 7.05). This mixture was allowed
to incubate for 20–30 min and then added dropwise to the cells. After
incubation of the cells with DNA for 4–5 h, the media were removed and
replaced with fresh media. Cells were not glycerol-shocked. On the
following day, the cells were serum-starved overnight in 0.1% fetal
bovine serum. On the second day following transfection, cells were
stimulated with EGF (100 ng/ml) for 5 h at 37 °C or left untreated. Cells
were then gently washed with phosphate-buffered saline, which had
been warmed to 37 °C to prevent dislodging of the cells from the dish.
Cells were then processed as described previously (24). Lysates (5 ml)
were read on a MONOLIGHT 2010 luminometer using enhanced
chemiluminescent reagents (Analytical Luminescence, San Diego, CA).
All assays were performed in duplicate, and the results presented are
the average of at least three independent transfections.
For analysis of Erk activity, 106 293 cells in a 100-mm tissue culture
plate were transfected with an expression construct encoding an HA
epitope-tagged Erk-2 along with the various dominant negative con-
structs. On the following day, cells were starved overnight in 0.1% fetal
bovine serum. On the second day following transfection, cells were
either stimulated with EGF (100 ng/ml for 5 min) or left untreated.
Cells were washed in phosphate-buffered saline warmed to 37 °C and
lysed in 1 ml of cold PLC-LB (50 mM HEPES, pH 7.5, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM magnesium chloride,
100 mM sodium flouride) supplemented with 1 mM vanadate, 10 mg/ml
leupeptin, and 10 mg/ml aprotinin. Insoluble debris was pelleted in a
microcentrifuge for 3–5 min at 4 °C. Equal amounts of protein from
each sample were then immunoprecipitated with a hemagglutinin an-
tibody (Babco; 1:200 dilution). These immunoprecipitates were fraction-
ated on SDS-PAGE and transferred to Immobilon-P filters. The result-
ing filters were stained with Ponceau S to visualize the proteins and
then cut just below the immunoglobulin heavy chain. This step de-
creases the background obtained from reactivity of the heavy chain
protein with the secondary antibody. The filters were then probed with
an antibody that recognizes the dually phosphorylated (phosphothreo-
nine and phosphotyrosine), activated form of MAPK (Anti-ACTIVE
MAPK polyclonal antibody; Promega). The blots were stripped accord-
ing to the manufacturer’s protocol for the ECL kits and reprobed with
an anti-HA monoclonal antibody to determine the amount of expressed
HA-tagged Erk-2. The ratio of activated Erk-2 to total Erk-2 was de-
termined by densitometric analysis. Results were standardized against
the vector-transfected cells without EGF treatment.
Generation of EGFR-transformed Cell Lines—EGFR-transformed
NIH/3T3 cells were generated by transfection of a murine leukemic
virus-EGFR construct into cells and selection in growth medium sup-
plemented with 400 mg/ml G418. The resulting G418-resistant colonies
were then passaged once as a population and allowed to grow to con-
fluence. Transformed foci emerged within 10–14 days after passaging.
The resulting transformed population of cells were further transfected
with expression constructs either corresponding to vector alone or en-
coding ShcC SH2 or PTB, Grb2 SH2, or p120 Ras GAP SH2-SH3-SH2.
Cells were selected in growth medium supplemented with 400 mg/ml
hygromycin and 400 mg/ml G418, and the resulting drug-resistant
colonies were pooled together and analyzed as described.
Transformation Assays—To test for anchorage-independent growth
in soft agar, 103 cells from each of the EGFR-transformed lines trans-
fected with pCGN-hyg, pCGN-ShcC PTB, or pCGN ShcC SH2 were
plated in triplicate in media containing 0.3% soft agar essentially as
described (25). Colonies were examined after 3–4 weeks. For the focus
formation assays, NIH/3T3 cells (2.5 3 105) cells were plated in 60-mm
dishes and on the following day were transfected with 0.5 mg of pSV2
NeuT plasmid along with 2 mg of the various dominant negatives. Each
condition was tested in triplicate, and the results were averaged.
Western Blot Analysis of the EGFR-transformed Cell Lines—EGFR-
transformed cell lines expressing the various dominant negative pro-
teins were lysed in PLC-LB as described above. Equal amounts of
protein were fractionated on a 12.5% SDS-PAGE and transferred to
Immobilon-P membranes. The membranes were then cut into different
portions and probed with antibodies directed against the EGFR (Up-
state Biotechnology, Inc.), ShcA (Upstate Biotechnology), or the HA
epitope (Babco). Reactive bands were visualized using the Enhanced
Chemiluminescent kit (Amersham Pharmacia Biotech).
For analysis of 293 cels, 1.25 3 106 cells/100-cm dish were trans-
fected with constructs encoding the various dominant negative proteins
(5 mg/dish). Cells were then starved overnight in 0.1% fetal bovine
serum. On the following day, cells were stimulated with EGF (100
ng/ml) for 5 min and then lysed in PLC-LB. Equal amounts of protein (1
mg) from each sample were subjected to immunoprecipitation with an
antibody specific to the human EGFR (Ab3, NeoMarkers, Inc.). Immu-
noprecipitates were then fractionated on a 12.5% SDS-PAGE, trans-
fected to Immobilon-P membranes, and probed with an antibody to
ShcA (Upstate Biotechnology). Bands were visualized using the En-
hanced Chemiluminescent kit (Amersham Pharmacia Biotech).
RESULTS
Expression of ShcC SH2 but Not PTB Domain Inhibits EGF
Activation of MAP Kinase—Activation of the EGFR by EGF
results in the recruitment of the Shc-Grb2-Sos complex to the
activated receptor, thereby leading to Ras activation (7). Acti-
vated Ras, in turn, activates the Raf-Erk cascade. Given the
ability of ShcC to bind to the activated EGFR receptor through
both its SH2 and PTB domains in vitro (2), we tested whether
expression of either of these domains individually could inhibit
the function of the EGFR (Fig. 1). As shown in Fig. 1A, each of
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the dominant negatives is expressed at similar levels in 293
cells. Since the GAP SH2-SH3-SH2 construct lacked an HA
epitope, we performed Western blot analysis with a GAP-spe-
cific antiserum, which indicated that this protein was also
expressed in these cells (data not shown).
Next we tested if expression of either the ShcC PTB or SH2
domain could inhibit EGF induction of Erk activity. Since the
p42/p44 Erks activate the transcription factor Elk-1 through
phosphorylation of the transcriptional activation domain, we
utilized a transient reporter assay in which we measure acti-
vation of a chimeric Gal4-Elk-1 transcription factor consisting
of the Gal4 DNA binding domain linked to the Elk-1 transcrip-
tional activation domain (24). Expression of the ShcC SH2
domain blocked greater than 70% of the EGF-dependent acti-
vation of Elk-1, whereas expression of the PTB domain did not
appear to significantly impact on Elk-1 activation by EGF (Fig.
1B). The inhibition by the SH2 domain was dependent on
phosphotyrosine binding as mutation of an Arg to Lys in the
conserved FLVRES sequence abolished inhibition (data not
shown). Expression of the SH2 domain of Grb2 also inhibited
EGF activation of Elk-1 as previously shown (26), since Grb2
can interact with the activated EGFR, either directly or
through Shc, via its SH2 domain (27, 28). In contrast, no
inhibition of Elk-1 was seen when the isolated SH2-SH3-SH2
region of p120 Ras GAP was expressed (Fig. 1B) (29), indicating
that the inhibition seen with the ShcC SH2 was not a nonspe-
cific property of all SH2 domains. Furthermore, neither the
SH2 nor the PTB domains inhibited Elk-1 activation by acti-
vated Ha-Ras(61L), suggesting that inhibition occurs at a point
upstream of Ras (Fig. 1C). Also, this result demonstrates that
the inhibition of EGFR signaling by the ShcC SH2 domain was
not due to nonspecific toxicity. In addition, expression of nei-
ther the SH2 nor the PTB domain inhibited activation of Elk-1
by the NPM-ALK oncoprotein, a member of the insulin family
of RTKs (23, 30, 31) (data not shown). Together these results
suggest that ShcC mediates EGFR activation of MAPKs pri-
marily through its SH2 domain.
Given that Elk-1 can be activated by a number of MAPK
family members, including Erk, p38, and Jnk (32, 33), we
tested whether expression of the ShcC mutants could inhibit
EGF-induced activation of Erk in 293 cells. Cells were trans-
fected with an expression construct encoding an HA epitope-
tagged MAPK/Erk2 protein (34) along with expression con-
structs encoding the various dominant negative proteins.
Following stimulation with EGF, HA epitope-tagged Erk-2 was
immunoprecipitated and analyzed for activation using a phos-
phospecific antibody that recognizes the dually phosphoryl-
ated, activated form of Erk-2. As shown in Fig. 2, stimulation of
Erk-2 phosphorylation was significantly inhibited by expres-
sion of the SH2, but not PTB, domain of ShcC. As with the
transient transcriptional assays, expression of the Grb2 SH2
domain also inhibited Erk-2 activation. In contrast to the tran-
sient assays, expression of the SH2-SH3-SH2 region of p120
Ras GAP inhibited EGF activation of Erk-2, suggesting that
the activation of Elk-1 shown in Fig. 1 occurs through an
Erk-independent pathway possibly through the activation of
Jnk or p38.2 These results support the notion that the ShcC
SH2 domain is a potent inhibitor of the EGF activation of Erks.
Expression of the ShcC SH2 Domain Inhibits Soft Agar
Growth of EGFR-transformed NIH/3T3 Cells—We next deter-
2 J. P. O’Bryan, G. Clark, and C. J. Der, manuscript in preparation.
then lysates were measured for luciferase activity. The results repre-
sent the average of four independent transfections each performed in
duplicate. Error bars represent S.E.
FIG. 1. ShcC dominant negative proteins inhibit Elk-1 activa-
tion by the EGFR. A, Western blot analysis of 293 cells transfected
with dominant negative adaptors. Equivalent amounts of proteins were
fractionated on SDS-PAGE, transferred to filters, and then Western
blotted with an antibody directed against the HA epitope or an antibody
directed against the GAP SH3 domain (data not shown). B, constructs
encoding the various dominant negative proteins were transfected into
293 cells to measure their effect on the EGF activation of Elk-1 as
described under “Experimental Procedures.” The results represent the
average of at least three independent transfections each performed in
duplicate. Error bars represent S.E. C, ShcC dominant negatives were
tested for their effect on Ras activation of Elk-1. Cells were transfected
with constructs encoding the ShcC dominant negatives along with an
expression vector encoding an activated Ras protein (Ha-Ras(61L)).
Cells were serum-starved overnight and lysed in luciferase buffer, and
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mined if expression of the SH2 or PTB domains of ShcC inhib-
ited aspects of EGFR-mediated transformation. To address this
possibility, we isolated mass transfected populations of EGFR-
transformed NIH/3T3 cells stably expressing the isolated ShcC
SH2 or PTB domains (see Fig. 5). The growth rates on plastic of
the resulting populations of cells were comparable with the
control, vector-transfected population of EGFR-transformed
cells. Thus, neither domain caused a significant inhibition of
cell proliferation, suggesting that inhibition of Erk activation is
separable from inhibition of growth. Similar results were seen
in 293 cells in that expression of the ShcC dominant negative
proteins did not appear to affect the proliferation of these cells
(data not shown). Although expression of the SH2 or PTB
domain did not cause a significant reversion in the transformed
morphology of cells, we did observe an impairment in their
ability to form colonies in soft agar (Fig. 3). Whereas control
vector-transfected cells formed large colonies in soft agar, the
SH2 domain-expressing cells showed a striking impairment in
their ability to form colonies. Although PTB domain-expressing
cells did form colonies, the efficiency was reduced (approxi-
mately 50%), and the colonies were smaller than those formed
by the vector-transfected EGFR-transformed cells (Fig. 3B).
Taken together, these results suggest that the ShcC SH2 do-
main, and to a lesser degree the PTB domain, mediates EGFR
signaling pathways that promote anchorage-independent
growth but not morphologic transformation by the EGFR. In-
deed, overexpression of Shc proteins was found to promote
growth in soft agar with little effect on the morphology of
NIH/3T3 cells (3).
The relative importance of the SH2 and PTB domains in
mediating growth transformation signaling pathways was also
observed for another EGFR family member, the ErbB2/Neu
RTK. Co-transfection of an expression construct encoding a
constitutively activated and transforming mutant of Neu (21)
along with the SH2 encoding plasmid resulted in a 75% reduc-
tion in Neu focus-forming activity (Fig. 4). In contrast, expres-
sion of the PTB domain resulted in only a 25% reduction in Neu
focus-forming activity. This inhibition was specific, since co-
expression of the ShcC SH2 or PTB domains did not signifi-
cantly impair the focus-forming activity of an activated Src
nonreceptor tyrosine kinase (SrcY527F) or the NPM-ALK
transforming protein (data not shown), both of which have been
shown to activate Shc proteins (23, 35).
The SH2 Domain Inhibits EGFR Signaling without Stable
Association with the Receptor—The EGFR contains two binding
sites for Shc proteins, Tyr1148 for the PTB domain and Tyr1173
for the SH2 domain (36, 37). We hypothesized that the domi-
nant negative proteins were exerting their inhibitory effect
through competition with endogenous Shc proteins for binding
to the activated EGFR. Therefore, we analyzed the EGFR-
transformed cell lysates described above for the association of
the activated receptor with the various mutant ShcC proteins.
As shown in Fig. 5A, all of the cell lines expressed approxi-
mately equal amounts of the EGFR. However, there was a
marked difference in the association of the dominant negative
proteins with the receptor. As predicted, the ShcC PTB and
Grb2 SH2 proteins were both found in complexes with the
receptor. However, the ShcC SH2 domain was only weakly
associated with the receptor. Analysis of whole cell lysates
indicated that the various dominant negatives were expressed
at similar levels, suggesting that the difference in association
of the EGFR with the different proteins was not due to differ-
ences in levels of expression (Fig. 5B). These results suggest
that although the SH2 domain is the more potent inhibitor of
EGFR function, this inhibition occurs in the absence of stable
association with the receptor.
In addition, we examined the association of endogenous
ShcA with the activated EGFR in the presence of the various
dominant negative proteins. Surprisingly, the dominant nega-
tives did not cause significant impairment of endogenous ShcA
association with the activated EGFR (Fig. 5). In the case of the
SH2 domain, this result is not surprising, given the lack of
stable association with the receptor in vivo. However, for the
PTB domain, the amount of ShcA may be limiting, given the
overexpression of the transfected EGFR. In this case, we may
not be able to detect a loss of endogenous ShcA binding, since
the PTB domain may be binding to a different pool of receptors
than endogenous ShcA. To test this possibility, we examined
the ability of the various dominant negative proteins to block
ShcA association with the EGFR in 293 cells, since these cells
express higher levels of the dominant negative proteins as
compared with NIH/3T3 cells. As shown in Fig. 5C, expression
of the ShcC SH2, Grb2 SH2, and GAP SH2-SH3-SH2 proteins
did not affect association of endogenous ShcA with the acti-
vated EGFR. However, expression of the PTB domain did par-
tially block ShcA binding to the EGFR. These results suggest
that the PTB domain is the region of Shc proteins that directs
association with the EGFR and that the SH2 domain may
interact with additional cellular components important for
EGFR function.
DISCUSSION
In this report, we describe a set of dominant negative ver-
sions of the ShcC adaptor protein and their effects on EGFR
function. Previous work from our laboratory (2, 38) and others
(1, 4) has shown that ShcC is a neural cell-specific adaptor
protein that, like the initially identified Shc protein, ShcA, also
binds receptor tyrosine kinases such as EGFR and TrkA. In
vitro binding studies suggest that specific tyrosine residues
within the cytoplasmic tail of the EGFR are important for Shc
binding via its PTB and/or SH2 domain. However, the relative
importance of these interactions for EGFR function in vivo
remains unclear. To address this question, we expressed the
isolated SH2 or PTB domain of ShcC to determine if they
served as dominant negative inhibitors of EGFR function. Of
FIG. 2. Expression of ShcC dominant negative proteins inhib-
its Erk-2 activation by EGF. 293 cells were transfected with an
expression vector encoding an HA epitope-tagged Erk-2 along with the
various dominant negative constructs. Erk-2 activity was assayed as
described under “Experimental Procedures.” The results shown repre-
sent the average of two independent transfections. Error bars represent
S.E. f, 2EGF; o, 1EGF.
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the two ShcC dominant negatives, the SH2 domain appears to
be the more efficacious inhibitor of EGFR function. This do-
main potently blocks EGF-induced activation of Elk-1 and
Erk-2. The inhibition by the SH2 domain was dependent on the
ability of this domain to bind tyrosine-phosphorylated proteins.
Additionally, the SH2 and PTB domains of ShcC inhibited both
focus formation and soft agar growth induced by overexpres-
sion of the EGFR family of RTKs. Expression of either the SH2
or PTB domain inhibited the growth of EGFR-transformed cells
in soft agar. Furthermore, both domains inhibited the forma-
tion of transformed foci induced by an activated form of
HER2/Neu.
During the preparation of this manuscript, we became aware
of the results of Kaiyi, et al.3 This group utilized a deletion
mutant in the CH1 domain of ShcA to block Neu-induced trans-
formation. As with our results, this Shc mutant did not inhibit
the association of endogenous Shc with the receptor. However,
in contrast to our findings, they did not see any effect of this
Shc mutant on Neu activation of MAPK, suggesting a mecha-
nism of inhibition distinct from that suggested by our results
with the EGFR.
Consistent with our finding that the SH2 domain inhibits
EGFR function, others have shown that DNA synthesis in-
duced by both EGF and platelet-derived growth factor, but not
insulin, is inhibited by microinjection of the isolated ShcA SH2
domain (39–42). In contrast, microinjection of the PTB domain
appeared to inhibit insulin-induced DNA synthesis (42); how-
ever, its effect on EGFR signaling was less clear. There are
conflicting reports as to the ability of the ShcA PTB domain to
block EGF-induced DNA synthesis (8, 42).
Although both the PTB and SH2 domains inhibited EGFR-
mediated transformation, only the PTB domain formed stable
complexes with the receptor. Our results are consistent with
the notion that the PTB domain promotes Shc protein interac-
tion with the EGFR, leaving the SH2 domain to interact with
additional cellular components necessary for EGFR signaling.
This idea is supported by several lines of evidence. First, the
3 K. Li, R. Shao, and M.-C. Hung, personal communication.
FIG. 3. ShcC SH2 and PTB domains
inhibit soft agar growth of EGFR-
transformed NIH/3T3 cell lines.
EGFR-transformed NIH/3T3 cells were
stably transfected with empty vector or
with PTB or SH2 expression constructs.
Stable cell lines were then tested for their
ability to form colonies in soft agar as
described under “Experimental Proce-
dures.” A, colonies were stained and then
counted. The result shown represents the
average of three wells for each cell line.
S.E. are indicated with bars. B, colonies
formed by EGFR-transformed cells ex-
pressing the ShcC PTB domain are
smaller than those formed by vector con-
trol cells.
FIG. 4. ShcC SH2 and PTB domains inhibit Neu-induced focus
formation. NIH/3T3 cells were co-transfected with 0.5 mg of an acti-
vated Neu expression vector per dish along with 2 mg of the indicated
dominant negative expression construct. Foci were stained after 28
days and counted. The results shown are the average of triplicate
transfections. S.E. values are indicated with bars.
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PTB binding site of the EGFR, Tyr1148, appears to be the
predominant Shc binding site as assessed through mutational
analysis of the EGFR (37) as well as comparison of the binding
affinities of both the SH2 and PTB domains of ShcA for ty-
rosine-phosphorylated phosphopeptides (43). Second, deletions
or mutations of the carboxyl terminus of the EGFR that remove
the autophosphorylation sites abolish interaction of the mutant
receptors with Shc yet inhibit neither the phosphorylation of
Shc by the mutant receptors nor the signaling functions of the
mutant receptors (8–10). Third, mutations in the ShcA PTB
domain that impair binding to phosphotyrosine inhibit inter-
action of ShcA with the EGFR although a functional SH2
domain is present (44). Fourth, as stated above, microinjection
of a GST-SH2 fusion protein of ShcA into cells inhibits EGF-
induced mitogenesis (39, 40, 42). However, the SH2 domain
continues to inhibit even when injected 10 min following stim-
ulation with EGF, suggesting that the SH2 domain interac-
tions are important for EGF-induced signals distal to the re-
ceptor (40). And finally, in vitro binding experiments with the
isolated SH2 domains from all three Shc family members indi-
cate that this domain interacts with a number of tyrosine-
phosphorylated cellular proteins (2).
Our data support the premise that the SH2 domain is im-
portant for signaling events downstream of the receptor. These
events may involve interaction with either membrane-bound
proteins, cytosolic proteins, or both. We believe there may be a
cytosolic component(s) to which the isolated SH2 domain binds
in vivo, thereby blocking interaction with the endogenous Shc
proteins. This idea is supported by our finding that the isolated
ShcC SH2 domain is found predominantly in the cytosol of cells
both in the presence and absence of EGF stimulation.4 Fur-
thermore, the interaction of Shc with this additional protein
may be important for activation of Ras and hence MAPK.
Although the ShcC dominant negative proteins inhibited two
members of the EGFR family of RTKs (EGFR and Neu), ex-
pression of these domains does not inhibit all RTKs, suggesting
that the ShcC dominant negatives possess specificity in their
inhibitory action. Coexpression of the ShcC dominant negative
proteins with an activated form of the ALK RTK, a member of
the insulin receptor family (23, 30, 31), did not block signaling
as measured either by activation of Elk-1 in transient reporter
assays or focus formation assays in NIH/3T3 cells.4 Although
the ALK protein contains a consensus Shc PTB binding site in
the cytoplasmic tail, deletion of this region does not impair
transforming activity, suggesting that interaction with Shc
proteins is not required for transformation by the receptor (23).
Furthermore, since the SH2 domain was not inhibitory, this
result suggests that the proposed target of the SH2 domain
that is important for EGFR signaling is not important for ALK
signaling. Together, these findings suggest that the ShcC dom-
inant negative proteins exhibit specificity with regard to inhi-
bition of RTKs.
The data presented here suggest that Shc proteins function
in a complex manner to regulate signaling events. In the case of
the EGFR, our results are consistent with the notion that the
PTB domain mediates the interaction of Shc with the receptor
while the SH2 domain contacts additional cellular components
important for signaling by the receptor. This paradigm may not
apply for all RTKs as discussed above for ALK. Future exper-
iments will help define the downstream targets of Shc proteins
and their importance in signal transduction cascades, particu-
larly those mediated by the EGFR.
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